- Supported exchanges /
- LSE /
- 0RA9.LSE
Abivax S.A. (0RA9 LSE) stock market data APIs
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Abivax S.A. Financial Data Overview
| 10.66 | |
| 10.66 | |
| - | |
| 10.66 | |
| 10.66 | |
| 7.92-16.92 | |
| 97 865 K | |
| 9 981 K | |
| 9 053 K | |
| 1.452 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Abivax S.A. Fundamental Data is available in our Financial Data APIs
- Net Revenue 9 053 K
- EBITDA -169 720 000
- Earnings Per Share -2.47
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Abivax S.A. Earnings via APIs
- Latest Release 2024-09-09
- EPS/Forecast NaN
Get Abivax S.A. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
